Abstract
This review explores the function of estrogen receptors (ERs) and their signaling pathways, and their involvement in the pathogenesis and management of prostate cancer (PCa). We pay special attention to (1) traditional estrogen receptors (ERα and ERβ) and the alternate estrogen receptor, G protein-coupled receptor 30 (GPR30); (2) therapeutic utility of estrogen and antiestrogens; (3) impact of genetic variants of ERs on prostate cancer risk; (4) epigenetic regulation of ERs; (5) downstream signaling of ERs; (6) diagnostic and prognostic value of these receptors; and (7) interaction between ERβ and aryl hydrocarbon receptor or androgen receptor. We also explore (a) the expression patterns of ERs and their spliced isoforms during normal development and the development and progression of PCa; (b) the divergent roles of the estrogen receptors as tumor suppressors and tumor promoters; (c) the possibility of developmental origin of the disease; and (d) the regulation of estrogen receptors via epigenetic modifications such as DNA methylation, histone modification, and microRNA processing. We also review the potential clinical application of various phytoestrogens (genistein, equol, dihydrogenistein, and daidzein), selective estrogen-receptor modulators (SERMs: tamoxifen, toremifene, and raloxifene), pure estrogen antagonists (e.g., fulvestrant), and transdermal estradiol delivered as preventive agents and first-line therapies or combinatory agents. We highlight the need for further studies of the role of ERs in epithelial–mesenchymal transition, prostate stem/progenitor cell function, and cross talk with other nuclear receptors and address the prospect of devising strategies for primordial prevention of PCa through improvements in the understanding of estrogen imprinting in early life.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J et al (2004) Human prostate cancer risk factors. Cancer 101:2371–2490
Ho SM (2004) Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 91:491–503
Ho SM, Leung YK, Chung I (2006) Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann N Y Acad Sci 1089:177–193
American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta, GA
Richards RJ, Svec F, Bao W, Srinivasan SR, Berenson GS (1992) Steroid hormones during puberty: racial (black-white) differences in androstenedione and estradiol–the Bogalusa Heart Study. J Clin Endocrinol Metab 75:624–631
Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B (1986) Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76:45–48
Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N et al (2007) Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 92:2519–2525
Abdelrahaman E, Raghavan S, Baker L, Weinrich M, Winters SJ (2005) Racial difference in circulating sex hormone-binding globulin levels in prepubertal boys. Metabolism 54:91–96
Orwoll ES, Nielson CM, Labrie F, Barrett-Connor E, Cauley JA, Cummings SR et al (2010) Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab 95:E151–E160
de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Maas PJ et al (1991) Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res 51:3445–3450
Bosland MC (1999) Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 35:459–463
Daniels NA, Nielson CM, Hoffman AR, Bauer DC (2010) Sex hormones and the risk of incident prostate cancer. Urology 76:1034–1040
Ricke WA, Wang Y, Cunha GR (2007) Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 75:871–882
Assenza GE, Autore C, Marino B (2007) Hypertrophic cardiomyopathy in a patient with Down's syndrome. J Cardiovasc Med (Hagerstown) 8:463–464
Prins GS, Huang L, Birch L, Pu Y (2006) The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci 1089:1–13
Prins GS, Korach KS (2008) The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73:233–244
Cheung SY, Choi HL, James AE, Chen ZY, Huang Y, Chan FL (2003) Spontaneous mammary tumors in aging Noble rats. Int J Oncol 22:449–457
Tam NN, Leav I, Ho SM (2007) Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am J Pathol 171:1334–1341
Noble RL (1977) The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 37:1929–1933
Yatkin E, Bernoulli J, Talvitie EM, Santti R (2009) Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. Int J Androl 32:399–410
Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW et al (2006) Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 118:2123–2131
Bernoulli J, Yatkin E, Konkol Y, Talvitie EM, Santti R, Streng T (2008) Prostatic inflammation and obstructive voiding in the adult Noble rat: impact of the testosterone to estradiol ratio in serum. Prostate 68:1296–1306
Yatkin E, Bernoulli J, Lammintausta R, Santti R (2008) Fispemifene [Z-2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis. J Pharmacol Exp Ther 327:58–67
Bernoulli J, Yatkin E, Laakso A, Anttinen M, Bosland M, Vega K et al (2008) Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. Prostate 68:728–739
Risbridger GP, Ellem SJ, McPherson SJ (2007) Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 39:183–188
Warner M, Gustafsson JA (2010) The role of estrogen receptor beta (ERbeta) in malignant diseases–a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 396:63–66
Ho SM, Lee MT, Lam HM, Leung YK (2011) Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinol Metab Clin North Am 40:591–614, ix
Hall JM, McDonnell DP, Korach KS (2002) Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol 16:469–486
Hyder SM, Chiappetta C, Stancel GM (1999) Interaction of human estrogen receptors alpha and beta with the same naturally occurring estrogen response elements. Biochem Pharmacol 57:597–601
Hall JM, Korach KS (2002) Analysis of the molecular mechanisms of human estrogen receptors alpha and beta reveals differential specificity in target promoter regulation by xenoestrogens. J Biol Chem 277:44455–44461
Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863–870
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT et al (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252–4263
Danielian PS, White R, Lees JA, Parker MG (1992) Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025–1033
Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA (2005) Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26:465–478
Routledge EJ, White R, Parker MG, Sumpter JP (2000) Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J Biol Chem 275:35986–35993
Morito K, Hirose T, Kinjo J, Hirakawa T, Okawa M, Nohara T et al (2001) Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 24:351–356
Katzenellenbogen BS, Sun J, Harrington WR, Kraichely DM, Ganessunker D, Katzenellenbogen JA (2001) Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann N Y Acad Sci 949:6–15
Dondi D, Piccolella M, Biserni A, Della TS, Ramachandran B, Locatelli A et al (2010) Estrogen receptor beta and the progression of prostate cancer: role of 5alpha-androstane-3beta,17beta-diol. Endocr Relat Cancer 17:731–742
Osborne CK, Schiff R, Fuqua SA, Shou J (2001) Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7:4338s–4342s
Tremblay GB, Giguere V (2002) Coregulators of estrogen receptor action. Crit Rev Eukaryot Gene Expr 12:1–22
Wang D, Hu L, Zhang G, Zhang L, Chen C (2010) G protein-coupled receptor 30 in tumor development. Endocrine 38:29–37
Maggiolini M, Picard D (2010) The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 204:105–114
Park II, Zhang Q, Liu V, Kozlowski JM, Zhang J, Lee C (2009) 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology 150:4594–4605
Takada Y, Kato C, Kondo S, Korenaga R, Ando J (1997) Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun 240:737–741
Owman C, Blay P, Nilsson C, Lolait SJ (1996) Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt’s lymphoma and widely distributed in brain and peripheral tissues. Biochem Biophys Res Commun 228:285–292
Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ (1997) Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45:607–617
O’Dowd BF, Nguyen T, Marchese A, Cheng R, Lynch KR, Heng HH et al (1998) Discovery of three novel G-protein-coupled receptor genes. Genomics 47:310–313
Wang C, Prossnitz ER, Roy SK (2007) Expression of G protein-coupled receptor 30 in the hamster ovary: differential regulation by gonadotropins and steroid hormones. Endocrinology 148:4853–4864
Thomas P, Pang Y, Filardo EJ, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146:624–632
Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y (2006) G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun 346:904–910
Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J et al (2007) Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 148:3236–3245
Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625–1630
Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C et al (2007) Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol 2:536–544
Wang C, Prossnitz ER, Roy SK (2008) G protein-coupled receptor 30 expression is required for estrogen stimulation of primordial follicle formation in the hamster ovary. Endocrinology 149:4452–4461
Matsuda K, Sakamoto H, Mori H, Hosokawa K, Kawamura A, Itose M et al (2008) Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. Neurosci Lett 441:94–99
Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D et al (2008) G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 149:4846–4856
Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS et al (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2:207–212
Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB (2008) The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol 109:350–353
Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16:70–84
Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S et al (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20:631–646
Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A et al (2006) 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 70:1414–1423
Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28:523–532
Thomas P, Dong J (2006) Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 102:175–179
Madeo A, Maggiolini M (2010) Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 70:6036–6046
Adams JY, Leav I, Lau KM, Ho SM, Pflueger SM (2002) Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate. Prostate 52:69–81
Shapiro E, Huang H, Masch RJ, McFadden DE, Wilson EL, Wu XR (2005) Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. J Urol 174:2051–2053
Rubio-Stipec M, Bird H, Canino G, Gould M (1990) The internal consistency and concurrent validity of a Spanish translation of the Child Behavior Checklist. J Abnorm Child Psychol 18:393–406
Fixemer T, Remberger K, Bonkhoff H (2003) Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54:79–87
Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S et al (2001) Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 61:5331–5335
Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O et al (2001) Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61:1919–1926
Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J et al (2001) Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159:79–92
Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Arenas MI et al (2001) Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 168:447–454
Torlakovic E, Lilleby W, Torlakovic G, Fossa SD, Chibbar R (2002) Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum Pathol 33:646–651
Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L et al (2010) Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 17:675–689
Taplin ME, Ho SM (2001) Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab 86:3467–3477
Weihua Z, Warner M, Gustafsson JA (2002) Estrogen receptor beta in the prostate. Mol Cell Endocrinol 193:1–5
Kawashima H, Nakatani T (2012) Involvement of estrogen receptors in prostatic diseases. Int J Urol 19:512–522
Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S et al (2009) Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice. Endocrinology 150:251–259
Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T et al (2005) Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate 65:101–109
Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF et al (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 95:15677–15682
Jiang J, Chang HL, Sugimoto Y, Lin YC (2005) Effects of age on growth and ERbeta mRNA expression of canine prostatic cells. Anticancer Res 25:4081–4090
Signoretti S, Loda M (2001) Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol 159:13–16
Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA et al (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092–3096
Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV et al (2011) Estrogen receptor alpha and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab 96:E368–E372
Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM et al (2006) Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol 175:523–527
Gupta L, Thakur H, Sobti RC, Seth A, Singh SK (2010) Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population. Mol Cell Biochem 335:255–261
Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B et al (2003) Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 98:1411–1416
Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, Scollen S et al (2006) Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer 56:31–39
Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S (2012) Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: Evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog 51(Suppl 1):E104–E117
Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA et al (2013) Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate 73(1):1–10
Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L et al (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 16:969–978
Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED et al (2007) Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16:165–168
Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL et al (2009) Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 18:1869–1880
Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K (2009) Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer. PLoS One 4:e6523
Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW et al (2010) Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev 19:1871–1878
McIntyre MH, Kantoff PW, Stampfer MJ, Mucci LA, Parslow D, Li H et al (2007) Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev 16:2233–2236
Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, Cormier L et al (2009) Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol 160:101–106
Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R (2003) Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog 37:202–208
Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F, Augustsson-Balter K, Adami HO et al (2006) Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res 12:1936–1941
Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D et al (2007) Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 16:1973–1981
Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O (2010) GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. J Steroid Biochem Mol Biol 118:7–12
Kakinuma N, Sato M, Yamada T, Kohu K, Nakajima M, Akiyama T et al (2005) Cloning of novel LERGU mRNAs in GPR30 3′ untranslated region and detection of 2 bp-deletion polymorphism in gastric cancer. Cancer Sci 96:191–196
Peng Y, Liang G, Pei Y, Ye W, Liang A, Su P (2012) Genomic polymorphisms of G-protein estrogen receptor 1 are associated with severity of adolescent idiopathic scoliosis. Int Orthop 36:671–677
Shidlovskaia NK, Dubrovina TI, Poliak RI (1991) [Formation of target cells in the immunocompetent organ (spleen) of mice with experimental infection caused by influenza A viruses with various properties]. Vestn Akad Med Nauk SSSR: 23–27
Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T (2001) Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet 128:31–34
National Center for Biotechnology Information. ESR1 estrogen receptor 1 [Homo sapiens]. 11-25-2012. National Center for Biotechnology Information, U.S. National Library of Medicine, NCBI. 12-8-2012
Ye Q, Chung LW, Cinar B, Li S, Zhau HE (2000) Identification and characterization of estrogen receptor variants in prostate cancer cell lines. J Steroid Biochem Mol Biol 75:21–31
Taylor SE, Patel II, Singh PB, Nicholson CM, Stringfellow HF, Gopala Krishna RK et al (2010) Elevated oestrogen receptor splice variant ERalphaDelta5 expression in tumour-adjacent hormone-responsive tissue. Int J Environ Res Public Health 7:3871–3889
Hirata S, Shoda T, Kato J, Hoshi K (2001) The multiple untranslated first exons system of the human estrogen receptor beta (ER beta) gene. J Steroid Biochem Mol Biol 78:33–40
Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC et al (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22:7600–7606
Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S et al (2008) Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5′-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99:2365–2372
Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y et al (2004) Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164:2003–2012
Zhang X, Leung YK, Ho SM (2007) AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0 N promoter in prostate cancer cells. Oncogene 26:7346–7354
Leung YK, Lee MT, Lam HM, Tarapore P, Ho SM (2012) Estrogen receptor-beta and breast cancer: translating biology into clinical practice. Steroids 77:727–737
Wethmar K, Smink JJ, Leutz A (2010) Upstream open reading frames: molecular switches in (patho)physiology. Bioessays 32:885–893
Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL et al (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75–78
Poola I, Abraham J, Baldwin K, Saunders A, Bhatnagar R (2005) Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization. Endocrine 27:227–238
Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 103:13162–13167
Fujimura T, Takahashi S, Urano T, Ogawa S, Ouchi Y, Kitamura T et al (2001) Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 289:692–699
Nagasaki S, Nakamura Y, Maekawa T, Akahira J, Miki Y, Suzuki T et al (2012) Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor betacx in human prostate carcinoma. Neoplasma 59:224–232
Dey P, Jonsson P, Hartman J, Williams C, Strom A, Gustafsson JA (2012) Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 26(12):1991–2003
Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150:12–27
Tang WY, Ho SM (2007) Epigenetic reprogramming and imprinting in origins of disease. Rev Endocr Metab Disord 8:173–182
Koch CM, Andrews RM, Flicek P, Dillon SC, Karaoz U, Clelland GK et al (2007) The landscape of histone modifications across 1 % of the human genome in five human cell lines. Genome Res 17:691–707
Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC et al (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410:120–124
Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al (2007) High-resolution profiling of histone methylations in the human genome. Cell 129:823–837
He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531
Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A et al (2001) Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 86:2051–2055
Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R (2000) Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 60:702–706
Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S et al (2002) Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 94:384–390
Moriyama-Gonda N, Shiina H, Terashima M, Satoh K, Igawa M (2008) Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha. BJU Int 101:485–491
Yao Q, He XS, Zhang JM, He J (2006) Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma. Zhonghua Nan Ke Xue 12:28–31
Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, Kane CJ et al (2004) Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun 321:455–461
Nojima D, Li LC, Dharia A, Perinchery G, Ribeiro-Filho L, Yen TS et al (2001) CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 92:2076–2083
Bovenzi V, Momparler RL (2001) Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 48:71–76
Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D et al (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81:177–186
Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19:1740–1751
Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC (2008) DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 68:210–222
Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH et al (2007) The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 6:2626–2633
Klinge CM (2012) miRNAs and estrogen action. Trends Endocrinol Metab 23:223–233
Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S et al (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8:529–538
Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM et al (2010) Identification of the miR-106b 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3:ra29
Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH, et al (2011) MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol [Epub ahead of print]
Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL et al (2010) miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127:1363–1372
Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, et al (2012) CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene [Epub ahead of print]
Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S et al (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70:4778–4784
Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D et al (2001) Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 229:432–442
Chen M, Yeh CR, Chang HC, Vitkus S, Wen XQ, Bhowmick NA et al (2012) Loss of epithelial oestrogen receptor alpha inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models. J Pathol 226:17–27
Brody H, Goldman SF (1940) Metaplasia of the epithelium of the prostatic glands, utricle and urethra of the fetus and newborn infant. Arch Pathol Lab Med 29:494–540
Andrews GS (1951) The histology of the human foetal and prepubertal prostates. J Anat 85:44–54
Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS (2001) Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res 61:6089–6097
Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP (2008) Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 22:1512–1520
Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA et al (2003) The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res 63:6056–6062
Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62:1370–1376
Attia DM, Ederveen AG (2012) Opposing roles of ERalpha and ERbeta in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate 72:1013–1022
Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155:641–647
Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E et al (2006) Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176:965–970
Yu L, Wang CY, Shi J, Miao L, Du X, Mayer D et al (2011) Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells. Endocrinology 152:773–781
Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI et al (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98:6330–6335
Morani A, Warner M, Gustafsson JA (2008) Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Intern Med 264:128–142
Antal MC, Krust A, Chambon P, Mark M (2008) Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci USA 105:2433–2438
Couse JF, Curtis HS, Korach KS (2000) Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J Steroid Biochem Mol Biol 74:287–296
Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M (2000) Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127:4277–4291
Ji Q, Liu PI, Elshimali Y, Stolz A (2005) Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol Cell Endocrinol 229:103–110
Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA et al (2010) ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17:319–332
Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS et al (2004) Metastases of prostate cancer express estrogen receptor-beta. Urology 64:814–820
Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S et al (2009) Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119:1093–1108
Cheng J, Lee EJ, Madison LD, Lazennec G (2004) Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 566:169–172
Hurtado A, Pinos T, Barbosa-Desongles A, Lopez-Aviles S, Barquinero J, Petriz J et al (2008) Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells. Cell Oncol 30:349–365
Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A et al (2005) The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res 65:5445–5453
McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M et al (2010) Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 107:3123–3128
Nakajima Y, Akaogi K, Suzuki T, Osakabe A, Yamaguchi C, Sunahara N et al (2011) Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERbeta and KLF5. Sci Signal 4:ra22
Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK et al (2010) Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 17:1511–1523
Miroshnichenko II, Kudrin VS, Raevskii KS (1988) Effect of carbidine, sulpiride and haloperidol on levels of monoamines and their metabolites in the brain structures of rats. Farmakol Toksikol 51:26–29
Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232–240
The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281–1286
Cox RL, Crawford ED (1995) Estrogens in the treatment of prostate cancer. J Urol 154:1991–1998
Denis LJ, Griffiths K (2000) Endocrine treatment in prostate cancer. Semin Surg Oncol 18:52–74
Clemons J, Glode LM, Gao D, Flaig TW (2011) Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol 31:198–204
Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, et al (2012) Diethylstilbestrol in castration-resistant prostate cancer. BJU Int 110:E727–E735
Bosset PO, Albiges L, Seisen T, de la Motte RT, Phe V, Bitker MO et al (2012) Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int 110(11 Pt C):E826–E829
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927–937
Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK et al (1999) A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 5:2366–2373
Stein S, Zoltick B, Peacock T, Holroyde C, Haller D, Armstead B et al (2001) Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. Am J Clin Oncol 24:283–285
Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D et al (2003) A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. Acta Oncol 42:195–201
Lissoni P, Vigano P, Vaghi M, Frontini L, Giuberti C, Manganini V et al (2005) A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Res 25:3597–3599
Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB et al (2006) Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int 97:691–697
Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D et al (2010) Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 184:1316–1321
Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P et al (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179:152–155
Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MS (2011) Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol 186:2239–2244
Hill JC, Krishnaveni GV, Annamma I, Leary SD, Fall CH (2005) Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry. Acta Obstet Gynecol Scand 84:159–165
Boccardo F, Rubagotti A, Battaglia M, Di TP, Selvaggi FP, Conti G et al (2005) Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23:808–815
Bedognetti D, Rubagotti A, Conti G, Francesca F, De CO, Canclini L et al (2010) An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 57:238–245
Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM et al (2005) Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 103:717–723
Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC et al (2008) Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 102:442–445
Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (2003) Transdermal estradiol therapy for advanced prostate cancer–forward to the past? J Urol 169:1735–1737
Ockrim JL, Lalani e, Kakkar AK, Abel PD (2005) Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 174:527–533
Gerber GS, Zagaja GP, Ray PS, Rukstalis DB (2000) Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 55:97–101
Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S et al (2004) Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 172:2203–2207
Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D et al (2012) Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit 18:CR260–CR264
Leung YK, Gao Y, Lau KM, Zhang X, Ho SM (2006) ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia 8:242–249
Lau KM, LaSpina M, Long J, Ho SM (2000) Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60:3175–3182
Wei JJ, Wu X, Peng Y, Shi G, Basturk O, Yang X et al (2011) Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 17:1297–1305
Takeuchi I, Takaha N, Nakamura T, Hongo F, Mikami K, Kamoi K et al (2012) High mobility group protein AT-hook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells. Prostate 72:1124–1132
Kawashima H, Tanaka T, Cheng JS, Sugita S, Ezaki K, Kurisu T et al (2004) Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res 32:406–410
Bhattacharyya RS, Krishnan AV, Swami S, Feldman D (2006) Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 5:1539–1549
Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y et al (2006) Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol 100:24–33
Ho CK, Nanda J, Chapman KE, Habib FK (2008) Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol 197:483–491
Huynh H, Alpert L, Alaoui-Jamali MA, Ng CY, Chan TW (2001) Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate. J Endocrinol 171:109–118
Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D (1988) Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 80:1045–1053
Leav I, Merk FB, Kwan PW, Ho SM (1989) Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15:23–40
Tam NN, Szeto CY, Freudenberg JM, Fullenkamp AN, Medvedovic M, Ho SM (2010) Research resource: estrogen-driven prolactin-mediated gene-expression networks in hormone-induced prostatic intraepithelial neoplasia. Mol Endocrinol 24:2207–2217
Tam NN, Szeto CY, Sartor MA, Medvedovic M, Ho SM (2008) Gene expression profiling identifies lobe-specific and common disruptions of multiple gene networks in testosterone-supported, 17beta-estradiol- or diethylstilbestrol-induced prostate dysplasia in Noble rats. Neoplasia 10:20–40
Thompson CJ, Tam NN, Joyce JM, Leav I, Ho SM (2002) Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology 143:2093–2105
Fernandes SA, Gomes GR, Siu ER, Damas-Souza DM, Bruni-Cardoso A, Augusto TM et al (2011) The anti-oestrogen fulvestrant (ICI 182,780) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. Int J Androl 34:486–500
Chadha MK, Ashraf U, Lawrence D, Tian L, Levine E, Silliman C et al (2008) Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate 68:1461–1466
Gasent Blesa JM, Alberola CV, Giner MV, Giner-Bosch V, Provencio PM, Laforga Canales JB (2010) Experience with fulvestrant acetate in castration-resistant prostate cancer patients. Ann Oncol 21:1131–1132
Magee PJ, Rowland IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91:513–531
Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG et al (2003) Soy isoflavones: a safety review. Nutr Rev 61:1–33
Trock BJ, Hilakivi-Clarke L, Clarke R (2006) Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98:459–471
Taylor CK, Levy RM, Elliott JC, Burnett BP (2009) The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev 67:398–415
Sonn GA, Aronson W, Litwin MS (2005) Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 8:304–310
Jian L (2009) Soy, isoflavones, and prostate cancer. Mol Nutr Food Res 53:217–226
Lampe JW (2010) Emerging research on equol and cancer. J Nutr 140:1369S–1372S
Markiewicz L, Garey J, Adlercreutz H, Gurpide E (1993) In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol 45:399–405
Milligan SR, Balasubramanian AV, Kalita JC (1998) Relative potency of xenobiotic estrogens in an acute in vivo mammalian assay. Environ Health Perspect 106:23–26
deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM (2010) Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer 62:1036–1043
Ganry O (2005) Phytoestrogens and prostate cancer risk. Prev Med 41:1–6
Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D et al (2003) Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47:111–117
Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW (2003) Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 12:665–668
Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K et al (2004) Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95:65–71
Stattin P, Adlercreutz H, Tenkanen L, Jellum E, Lumme S, Hallmans G et al (2002) Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 99:124–129
Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC et al (1999) Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer 33:20–25
Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW, Overvad K et al (2009) Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 100:1817–1823
Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J et al (2004) The specific role of isoflavones in reducing prostate cancer risk. Prostate 59:141–147
Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK et al (2004) Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 64:510–515
Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ et al (2002) Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 11:1689–1696
Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W et al (2003) Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77:875–882
Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M et al (2003) Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 12:1213–1221
Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H et al (2011) Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer 63:889–898
Cavalieri EL, Rogan EG (2002) A unified mechanism in the initiation of cancer. Ann N Y Acad Sci 959:341–354
Lakhani NJ, Sarkar MA, Venitz J, Figg WD (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23:165–172
Sato F, Fukuhara H, Basilion JP (2005) Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo. Neoplasia 7:838–846
Reiner T, de las PA, Gomez LA, Perez-Stable C (2009) Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Cancer Lett 276:21–31
Ghosh R, Ganapathy M, Alworth WL, Chan DC, Kumar AP (2009) Combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 113:25–35
Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD et al (2012) Preclinical characterization of a novel diphenyl benzamide selective ERalpha agonist for hormone therapy in prostate cancer. Endocrinology 153:1070–1081
English HF, Santen RJ, Isaacs JT (1987) Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11:229–242
Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D et al (2002) Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 157:1257–1265
Ekbom A, Hsieh CC, Lipworth L, Wolk A, Ponten J, Adami HO et al (1996) Perinatal characteristics in relation to incidence of and mortality from prostate cancer. BMJ 313:337–341
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951
Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44 + alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 67:6796–6805
Gu G, Yuan J, Wills M, Kasper S (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67:4807–4815
Wang X, Kruithof-de JM, Economides KD, Walker D, Yu H, Halili MV et al (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461:495–500
Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI et al (1993) Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 85:394–398
Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR et al (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3:402–408
Hu WY, Shi GB, Lam HM, Hu DP, Ho SM, Madueke IC et al (2011) Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology 152:2150–2163
Hu WY, Shi GB, Hu DP, Nelles JL, Prins GS (2012) Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endocrinol 354:63–73
Hussain S, Lawrence MG, Taylor RA, Lo CY, Frydenberg M, Ellem SJ et al (2012) Estrogen receptor beta activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. PLoS One 7:e40732
Rajfer J, Coffey DS (1978) Sex steroid imprinting of the immature prostate. Long-term effects. Invest Urol 16:186–190
Arai Y, Suzuki Y, Nishizuka Y (1977) Hyperplastic and metaplastic lesions in the reproductive tract of male rats induced by neonatal treatment with diethylstilbestrol. Virchows Arch A Pathol Anat Histol 376:21–28
Arai Y, Mori T, Suzuki Y, Bern HA (1983) Long-term effects of perinatal exposure to sex steroids and diethylstilbestrol on the reproductive system of male mammals. Int Rev Cytol 84:235–268
Prins GS (1992) Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 130:2401–2412
Vorherr H, Messer RH, Vorherr UF, Jordan SW, Kornfeld M (1979) Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol. Biochem Pharmacol 28:1865–1877
McLachlan JA (1977) Prenatal exposure to diethylstilbestrol in mice: toxicological studies. J Toxicol Environ Health 2:527–537
Pylkkanen L, Santti R, Newbold R, McLachlan JA (1991) Regional differences in the prostate of the neonatally estrogenized mouse. Prostate 18:117–129
Vomsaal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC et al (1997) Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 94:2056–2061
Ho SM, Tang WY, de Belmonte FJ, Prins GS (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 66:5624–5632
Potischman N, Troisi R, Thadhani R, Hoover RN, Dodd K, Davis WW et al (2005) Pregnancy hormone concentrations across ethnic groups: implications for later cancer risk. Cancer Epidemiol Biomarkers Prev 14:1514–1520
Ekbom A, Wuu J, Adami HO, Lu CM, Lagiou P, Trichopoulos D et al (2000) Duration of gestation and prostate cancer risk in offspring. Cancer Epidemiol Biomarkers Prev 9:221–223
Chapin RE, Adams J, Boekelheide K, Gray LE Jr, Hayward SW, Lees PS et al (2008) NTP-CERHR expert panel report on the reproductive and developmental toxicity of bisphenol A. Birth Defects Res B Dev Reprod Toxicol 83:157–395
Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y (2002) Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod 17:2839–2841
Ranjit N, Siefert K, Padmanabhan V (2010) Bisphenol-A and disparities in birth outcomes: a review and directions for future research. J Perinatol 30:2–9
Schonfelder G, Wittfoht W, Hopp H, Talsness CE, Paul M, Chahoud I (2002) Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environ Health Perspect 110:A703–A707
Yamada H, Furuta I, Kato EH, Kataoka S, Usuki Y, Kobashi G et al (2002) Maternal serum and amniotic fluid bisphenol A concentrations in the early second trimester. Reprod Toxicol 16:735–739
Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M et al (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19:5406–5417
Re A, Aiello A, Nanni S, Grasselli A, Benvenuti V, Pantisano V et al (2011) Silencing of GSTP1, a prostate cancer prognostic gene, by the estrogen receptor-beta and endothelial nitric oxide synthase complex. Mol Endocrinol 25:2003–2016
Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT et al (2012) Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Mol Endocrinol 26:550–561
Scordalakes EM, Shetty SJ, Rissman EF (2002) Roles of estrogen receptor alpha and androgen receptor in the regulation of neuronal nitric oxide synthase. J Comp Neurol 453:336–344
Ando S, De AF, Rago V, Carpino A, Maggiolini M, Panno ML et al (2002) Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 193:121–128
Lanzino M, De AF, McPhaul MJ, Marsico S, Panno ML, Ando S (2005) Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem 280:20421–20430
Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G (2012) Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol 26:1941–1952
Luthy IA, Begin D, Labrie F (1988) Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17 beta-estradiol on the growth of androgen-sensitive Shionogi mammary carcinoma cells in culture. Endocrinology 123:1418–1424
Kumar MB, Tarpey RW, Perdew GH (1999) Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J Biol Chem 274:22155–22164
Madak-Erdogan Z, Katzenellenbogen BS (2012) Aryl hydrocarbon receptor modulation of estrogen receptor alpha-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. Toxicol Sci 125:401–411
Kharat I, Saatcioglu F (1996) Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor. Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem 271:10533–10537
Wang W, Smith R III, Safe S (1998) Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: modulation of hormone-induced cell cycle enzymes. Arch Biochem Biophys 356:239–248
Matthews J, Wihlen B, Thomsen J, Gustafsson JA (2005) Aryl hydrocarbon receptor-mediated transcription: ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-tetrachlorodibenzo-p-dioxin-responsive promoters. Mol Cell Biol 25:5317–5328
Kietz S, Thomsen JS, Matthews J, Pettersson K, Strom A, Gustafsson JA (2004) The Ah receptor inhibits estrogen-induced estrogen receptor beta in breast cancer cells. Biochem Biophys Res Commun 320:76–82
Caruso JA, Laird DW, Batist G (1999) Role of HSP90 in mediating cross-talk between the estrogen receptor and the Ah receptor signal transduction pathways. Biochem Pharmacol 58:1395–1403
Ohtake F, Baba A, Fujii-Kuriyama Y, Kato S (2008) Intrinsic AhR function underlies cross-talk of dioxins with sex hormone signalings. Biochem Biophys Res Commun 370:541–546
Ohtake F, Fujii-Kuriyama Y, Kato S (2009) AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem Pharmacol 77:474–484
Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R et al (2003) The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol 23:1843–1855
Acknowledgment
We thank Nancy Voynow for her professional editing of this manuscript. This work was supported by grants from NIH (ES020988, ES019480, ES006096, CA15776, and CA112532 to SMH), CDMRP Department of Defense (PC094619 to PT) and VA (BX000675 to SMH), and an internal funding source from the University of Cincinnati Medical Center.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Mayo Clinic
About this chapter
Cite this chapter
Ho, SM., Tarapore, P., Lee, MT., Leung, YK. (2013). Biology and Clinical Relevance of Estrogen Receptors in Prostate Cancer. In: Tindall, D. (eds) Prostate Cancer. Protein Reviews, vol 16. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6828-8_14
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6828-8_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6827-1
Online ISBN: 978-1-4614-6828-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)